BR112023021422A2 - Partículas interferentes terapêuticas para corona vírus - Google Patents

Partículas interferentes terapêuticas para corona vírus

Info

Publication number
BR112023021422A2
BR112023021422A2 BR112023021422A BR112023021422A BR112023021422A2 BR 112023021422 A2 BR112023021422 A2 BR 112023021422A2 BR 112023021422 A BR112023021422 A BR 112023021422A BR 112023021422 A BR112023021422 A BR 112023021422A BR 112023021422 A2 BR112023021422 A2 BR 112023021422A2
Authority
BR
Brazil
Prior art keywords
therapeutic
corona virus
interfering particles
particles
cov
Prior art date
Application number
BR112023021422A
Other languages
English (en)
Inventor
S Weinberger Leor
Robert Rodick
Sonali Chaturvedi
Original Assignee
The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone
Vxbiosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone, Vxbiosciences Inc filed Critical The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone
Publication of BR112023021422A2 publication Critical patent/BR112023021422A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ecology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)

Abstract

partículas interferentes terapêuticas para corona vírus. a presente invenção refere-se a composições de construtos e partículas de sars-cov-2 recombinante que podem interferir em ou bloquear a infecção de células não infectadas. as composições e métodos descritos neste documento são úteis para o tratamento de infecções por sars-cov-2.
BR112023021422A 2020-04-23 2022-04-25 Partículas interferentes terapêuticas para corona vírus BR112023021422A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014394P 2020-04-23 2020-04-23
PCT/US2021/028809 WO2021216979A2 (en) 2020-04-23 2021-04-23 Therapeutic interfering particles for corona virus
PCT/US2022/026223 WO2022226423A2 (en) 2020-04-23 2022-04-25 Therapeutic interfering particles for corona virus

Publications (1)

Publication Number Publication Date
BR112023021422A2 true BR112023021422A2 (pt) 2024-01-30

Family

ID=78270205

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022021562A BR112022021562A2 (pt) 2020-04-23 2021-04-23 Partículas interferentes terapêuticas para o coronavírus
BR112023021422A BR112023021422A2 (pt) 2020-04-23 2022-04-25 Partículas interferentes terapêuticas para corona vírus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022021562A BR112022021562A2 (pt) 2020-04-23 2021-04-23 Partículas interferentes terapêuticas para o coronavírus

Country Status (11)

Country Link
US (1) US20230151367A1 (pt)
EP (2) EP4153201A4 (pt)
JP (2) JP2023530049A (pt)
KR (2) KR20230028240A (pt)
CN (2) CN116472345A (pt)
AU (2) AU2021259847A1 (pt)
BR (2) BR112022021562A2 (pt)
CA (2) CA3181803A1 (pt)
IL (1) IL297547A (pt)
MX (1) MX2022013387A (pt)
WO (2) WO2021216979A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021259847A1 (en) * 2020-04-23 2022-12-15 The J. David Gladstone Institutes Therapeutic interfering particles for corona virus
WO2023015231A1 (en) * 2021-08-04 2023-02-09 The Regents Of The University Of California Sars-cov-2 virus-like particles
WO2023108299A1 (en) * 2021-12-17 2023-06-22 The Royal Institution For The Advancement Of Learning/Mcgill University Polypeptides capable of limiting the replication of a coronavirus
WO2023183794A2 (en) * 2022-03-24 2023-09-28 Mercury Bio, Inc. Direct production of sirnas in saccharomyces boulardii and packaging in extracellular vesicles (evs) for targeted gene silencing
WO2024175707A1 (en) 2023-02-22 2024-08-29 Helmholtz-Zentrum für Infektionsforschung GmbH A synthetic oligonucleotide for treating nidovirales infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005596A2 (en) * 2003-06-18 2005-01-20 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
WO2014151771A1 (en) * 2013-03-14 2014-09-25 The J. David Gladstone Institutes Compositions and methods for treating an immunodeficiency virus infection
US11141493B2 (en) * 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
AU2021259847A1 (en) * 2020-04-23 2022-12-15 The J. David Gladstone Institutes Therapeutic interfering particles for corona virus
RU2733361C1 (ru) * 2020-07-14 2020-10-01 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией
CN112029781B (zh) * 2020-08-14 2023-01-03 中山大学 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用

Also Published As

Publication number Publication date
EP4153201A4 (en) 2024-06-12
AU2021259847A1 (en) 2022-12-15
BR112022021562A2 (pt) 2023-02-07
WO2022226423A3 (en) 2022-12-15
JP2023530049A (ja) 2023-07-13
CA3181803A1 (en) 2021-10-28
MX2022013387A (es) 2023-05-17
CA3216708A1 (en) 2022-10-27
EP4153201A2 (en) 2023-03-29
WO2021216979A3 (en) 2021-11-25
CN117413063A (zh) 2024-01-16
WO2021216979A2 (en) 2021-10-28
US20230151367A1 (en) 2023-05-18
KR20230028240A (ko) 2023-02-28
IL297547A (en) 2022-12-01
EP4326398A2 (en) 2024-02-28
KR20240004551A (ko) 2024-01-11
JP2024515348A (ja) 2024-04-09
CN116472345A (zh) 2023-07-21
AU2022262662A9 (en) 2023-10-26
AU2022262662A1 (en) 2023-10-19
WO2022226423A2 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
BR112023021422A2 (pt) Partículas interferentes terapêuticas para corona vírus
BR112022022523A2 (pt) Anticorpos contra sars-cov-2
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR112015026258A2 (pt) composições e agentes terapêuticos e imunomoduladores, e usos dos mesmos
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112016026556A8 (pt) inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
BR112014027991A2 (pt) agentes para neutralização de influenza
EA202191736A1 (ru) Комбинированная терапия hbv
BR112021018409A2 (pt) Anticorpos e métodos para tratamento de infecção por influenza a
BR112022024149A2 (pt) Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno
BR112022016891A2 (pt) Vacina contra a infecção por vírus da peste suína africana
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
BR112022013480A2 (pt) Métodos de tratamento de coronavírus
BR112024000744A2 (pt) Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
BR112022001025A2 (pt) Inibidores de calicreína plasmática
BR112022001390A2 (pt) Inibidores de enzima
BR112021020605A2 (pt) Inibidor de mek para o tratamento de infecções virais e bacterianas
BR112021026193A2 (pt) Composições e métodos para tratar ou prevenir infecções oculares com filociclovir
BR112022019685A2 (pt) Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus
BR112022005896A2 (pt) Inibidores da mek para o tratamento de infecções causadas por hantavírus
UY38603A (es) Uso de virus oncolíticos para el tratamiento del cáncer
CO2020009043A2 (es) Anticuerpos humanos contra hemaglutinina de influenza